TAVR, a procedure used to
treat aortic valve stenosis, involves threading a long, thin, flexible tube, called a catheter, through the femoral artery in the leg to the heart.
Not exact matches
TAVR was first approved by the U.S. Food and Drug Administration (FDA) in 2011 to
treat patients with severe
aortic valve stenosis — a problem that occurs when the
valve in the heart's main artery doesn't open fully and forces the heart to work harder to pump blood — for whom standard surgical
valve replacement is too risky.
Referencing a research article in the same journal issue that found hospital websites failed to disclose risk information for transaortic
valve replacement (TAVR), a recently approved procedure to
treat patients whose
aortic valve does not open fully, London and Schenker pinpoint four risk concerns for patients seeking medical information online:
The FDA approved the CoreValve System to
treat patients with severe
aortic stenosis who are at high risk for surgery based on groundbreaking research showing the transcatheter heart
valve had superior survival rates at one year when compared to open - heart surgery, the current gold standard for
aortic valve replacement.
Patients
treated with the self - expanding TAVR device also reported improvement in NYHA classifications, durable improvement in hemodynamic
valve performance, and low rates of moderate or severe
aortic insufficiency.